The α2β1 binding domain of chondroadherin inhibits breast cancer-induced bone metastases and impairs primary tumour growth: A preclinical study

Cancer Letters

Volumn 358, Issue 1, 2015, Pages 67-75

  Rucci, Nadia ^a   Capulli, Mattia ^a   Olstad, Ole K ^b   Önnerfjord, Patrik ^c   Tillgren, Viveka ^c   Gautvik, Kaare M ^b   Heinegård, Dick ^c   Teti, Anna ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Bone metastases; Breast cancer; CyclicCHAD; Doxorubicin

Indexed keywords

ALENDRONIC ACID; ANTIMETASTATIC AGENT; CYCLICCHONDROADHERIN PEPTIDE; DOXORUBICIN; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 2; CHONDROADHERIN; SCLEROPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BREAST CANCER CELL LINE; CACHEXIA; CANCER INCIDENCE; CANCER INHIBITION; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MDA MB 231 CELL; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; PRIMARY TUMOR; PROTEIN BINDING; PROTEIN DOMAIN; TUMOR INVASION; TUMOR VOLUME; VISCERAL METASTASIS; ANIMAL; BONE NEOPLASMS; BREAST NEOPLASMS; DRUG EFFECTS; METABOLISM; OSTEOCLAST; OSTEOLYSIS; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; SECONDARY; TUMOR CELL LINE;

MUS;

ANIMALS; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; CACHEXIA; CELL LINE, TUMOR; DOXORUBICIN; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; INTEGRIN ALPHA2BETA1; MICE; OSTEOCLASTS; PROTEIN STRUCTURE, TERTIARY;

EID: 84921390231     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.12.032     Document Type: Article

References (27)

1. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889, 1:571-573.
2. Weilbaecher K.N., Guise T.A., McCauley L.K. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011, 11:411-425.
3. Roodman G.D. Mechanisms of bone metastasis. N. Engl. J. Med 2004, 350:1655-1664.
4. Clezardin P., Teti A. Bone metastasis: pathogenesis and therapeutic implications. Clin. Exp. Metastasis 2007, 24:599-608.
5. Capulli M., Olstad O.K., Onnerfjord P., Tillgren V., Muraca M., Gautvik K.M., et al. The c-terminl domain of chondroadherin: a new regulator of osteoclast motility counteracting bone loss. J. Bone Miner. Res 2014, 29:1833-1846.
6. Yoneda T., Sasaki A., Dunstan C., Williams P.J., Bauss F., De Clerck Y.A., et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with bisphophonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J. Clin. Invest 1997, 99:2509-2517.
7. Rucci N., Recchia I., Angelucci A., Alamanou M., Del Fattore A., Fortunati D., et al. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J. Pharmacol. Exp. Ther 2006, 318:161-172.
8. Lorensen W.E., Cline H.E. Marching cubes: a high resolution 3d surface construction algorithm. Comput. Graph. (ACM) 1987, 21:163-169.
9. Pratt W.K. Digital Image Processing 1991, Wiley, New York. 2nd ed.
10. Bouxsein M.L., Boyd S.K., Christiansen B.A., Guldberg R.E., Jepsen K.J., Müller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J. Bone Miner. Res 2010, 25:1468-1486.
11. Dempster D.W., Compston J.E., Drezner M.K., Glorieux F.H., Kanis J., Malluche H., et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res 2013, 28:2-17.
12. Pereira G.C., Silva A.M., Diogo C.V., Carvalho F.S., Monteiro P., Oliveira P.J. Drug-induced cardiac mitochondrial toxicity and protection: from doxorubicin to carvedilol. Curr. Pharm. Des 2011, 17:2113-2129.
13. Coleman R.E. Skeletal complications of malignancy. Cancer 1997, 80:1588-1594.
14. Coleman R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res 2006, 12:6243s-6249s.
15. Gaillard S., Stearns V. Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Res 2011, 13:205.
16. Coleman R.E. Risks and benefits of bisphosphonates. Br. J. Cancer 2008, 98:1736-1740.
17. Dunstan C.R., Felsenberg D., Seibel M.J. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat. Clin. Pract. Oncol 2007, 4:42-55.
18. Lipton A., Steger G.G., Figueroa J., Alvarado C., Solal-Celigny P., Body J.J., et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J. Clin. Oncol 2007, 25:4431-4437.
19. Sun L., Yu S. Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases: a systematic review and meta-analysis. Am. J. Clin. Oncol 2013, 36:399-403.
20. Ford J.A., Jones R., Elders A., Mulatero C., Royle P., Sharma P., et al. Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis. Eur. J. Cancer 2013, 49:416-430.
21. Gartrell B.A., Coleman R.E., Fizazi K., Miller K., Saad F., Sternberg C.N., et al. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer. Eur. Urol 2014, 65:278-286.
22. Peddi P., Lopez-Olivo M.A., Pratt G.F., Suarez-Almazor M.E. Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat. Rev 2013, 39:97-104.
23. Bokobza S.M., Ye L., Kynaston H., Jiang W.G. Growth and differentiation factor 9 (GDF-9) induces epithelial-mesenchymal transition in prostate cancer cells. Mol. Cell. Biochem 2011, 349:33-40.
24. Sawada Y., Tamada M., Dubin-Thaler B.J., Cherniavskaya O., Sakai R., Tanaka S., et al. Forced sensing by mechanical extension of the Src family kinase substrate p130Cas. Cell 2006, 127:1015-1026.
25. van der Flier S., Brinkman A., Look M.P., Kok E.M., Meijer-van Gelder M.E., Klijn J.G., et al. Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment. J. Natl Cancer Inst 2000, 92:120-127.
26. Storr S.J., Carragher N.O., Frame M.C., Parr T., Martin S.G. The calpain system and cancer. Nat. Rev. Cancer 2011, 11:364-374.
27. Storr S.J., Lee K.W., Woolston C.M., Safuan S., Green A.R., Macmillan R.D., et al. Calpain system protein expression in basal-like and triple-negative invasive breast cancer. Ann. Oncol 2012, 23:2289-2296.